



King's Research Portal

DOI:

[10.1016/j.jtcvs.2016.07.078](https://doi.org/10.1016/j.jtcvs.2016.07.078)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Nienaber, C. A., Sakalihasan, N., Clough, R. E., Aboukoura, M., Mancuso, E., Yeh, J. S. M., Defraigne, J.-O., Cheshire, N., Rosendahl, U. P., Quarto, C., & Pepper, J. (2016). Thoracic Endovascular Aortic Repair (TEVAR) in Proximal (Type A) Aortic Dissection: Ready for a Broader Application? *Journal of Thoracic and Cardiovascular Surgery*. Advance online publication. <https://doi.org/10.1016/j.jtcvs.2016.07.078>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights


Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript



Thoracic Endovascular Aortic Repair (TEVAR) in Proximal (Type A) Aortic Dissection: Ready for a Broader Application?

Christoph A. Nienaber, MD, PhD, Natzi Sakalihasan, MD, PhD, Rachel E. Clough, MD, PhD, Mohamed Aboukoura, MD, Enrico Mancuso, MD, James S.M. Yeh, MD, PhD, Jean-Olivier Defraigne, Nick Cheshire, MD, PhD, Ulrich Peter Rosendahl, MD, Cesare Quarto, MD, John Pepper, MD, PhD

PII: S0022-5223(16)31049-2

DOI: [10.1016/j.jtcvs.2016.07.078](https://doi.org/10.1016/j.jtcvs.2016.07.078)

Reference: YMTC 10824

To appear in: *The Journal of Thoracic and Cardiovascular Surgery*

Received Date: 17 May 2016

Revised Date: 6 July 2016

Accepted Date: 30 July 2016

Please cite this article as: Nienaber CA, Sakalihasan N, Clough RE, Aboukoura M, Mancuso E, Yeh JSM, Defraigne J-O, Cheshire N, Rosendahl UP, Quarto C, Pepper J, Thoracic Endovascular Aortic Repair (TEVAR) in Proximal (Type A) Aortic Dissection: Ready for a Broader Application?, *The Journal of Thoracic and Cardiovascular Surgery* (2016), doi: 10.1016/j.jtcvs.2016.07.078.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Thoracic Endovascular Aortic Repair (TEVAR) in**
2 **Proximal (Type A) Aortic Dissection:**
3 **Ready for a Broader Application?**

4

5 Christoph A. Nienaber^{1,5} MD, PhD, Natzi Sakalihasan² MD, PhD, Rachel E. Clough^{3,6}
6 MD, PhD, Mohamed Aboukoura⁴ MD, Enrico Mancuso¹ MD, James S. M. Yeh^{1,5} MD,
7 PhD, Jean-Olivier Defraigne², Nick Cheshire¹ MD, PhD, Ulrich Peter Rosendahl¹ MD,
8 Cesare Quarto¹ MD, John Pepper¹ MD, PhD

9

10 ¹ Royal Brompton Hospital, London, UK

11 ² Université Catholique de Liège, Belgium

12 ³ Aortic Centre, Hôpital Cardiologique, CHRU Lille, France

13 ⁴ University of Rostock, Department of Cardiology, Germany

14 ⁵ National Heart and Lung Institute, Imperial College London, UK

15 ⁶ Division of Imaging Sciences and Biomedical Engineering, King's College London

16

17 **Corresponding Author:**

18 Christoph A. Nienaber, MD, FESC, FACC

19 Cardiology and Aortic Centre

20 Royal Brompton Hospital

21 Royal Brompton and Harefield NHS Foundation Trust

22 Sydney Street

23 London SW3 6NP

24 UK

25 Phone: +44 (0)20 7352 8121 ext 2838

26 Fax: +44 (0)20 7351 8634

27 E-mail: c.nienaber@rbht.nhs.uk

28

29 **Word count** 3032

30 **Conflicts of interest** No potential conflicts exist for all authors.

31 **Funding** No funding was provided for this work.

32

33 **Abbreviations**

34

35	aTAAD	acute type A aortic dissection
36	CT	computed tomography
37	cTAAD	subacute or chronic type A aortic dissection
38	D	diameter
39	EKG	electrocardiogram
40	EuroSCORE II	European System for Cardiac Operative Risk Evaluation II
41	F	female
42	IRAD	International Registry of Acute Aortic Dissections
43	L	length
44	LCCA	left common carotid artery
45	M	male
46	N	number
47	NA	not applicable
48	NBS	non-bare stent
49	PA	pseudoaneurysm
50	RCA	right carotid artery
51	RFV	right femoral vein
52	SD	standard deviation
53	SG	stent-graft
54	TA	transapical
55	TAVR	transcatheter aortic valve replacement
56	TAx	transaxillary
57	TEVAR	thoracic endovascular aortic repair
58	TF	transfemoral

59

60

61 **ABSTRACT**

62

63 **OBJECTIVE:** Thoracic endovascular aortic repair (TEVAR) has demonstrated
64 encouraging results and is gaining increasing acceptance as a treatment option for
65 aortic aneurysms and dissections. Yet, its role in managing proximal aortic
66 pathologies is unknown - this is important because in proximal (Stanford type A)
67 aortic dissections, 10-30% are not accepted for surgery, and 30-50% are technically
68 amenable for TEVAR. We describe our case series of type A aortic dissections treated
69 using TEVAR.

70

71 **METHODS:** Between year 2009 and 2016, 12 patients with acute, subacute or
72 chronic type A aortic dissection with the proximal entry tear located between the
73 coronaries and brachiocephalic artery were treated with TEVAR at 3 centers. Various
74 stent-graft configurations were used to seal the proximal entry tear in the ascending
75 aorta under rapid pacing.

76

77 **RESULTS:** 12 patients (9 male, 3 female), mean age 81 ± 7 years, EuroSCORE II
78 9.1 ± 4.5 , underwent TEVAR for the treatment of type A aortic dissection. Procedural
79 success was achieved in 11/12 patients (91.7%). There was one intra-procedural death
80 and one minor stroke. No additional deaths at 30 days. At 36 months, there were 4
81 further deaths (all from non-aortic causes). The mean survival of these 4 deceased
82 was 23 months (range 15-36 months). Follow-up computed tomography demonstrated
83 favorable aortic remodeling.

84

85 **CONCLUSION:** TEVAR is feasible and reveals promising early results in selected
86 patients with type A aortic dissection who are poor candidates for surgical repair. The
87 current iteration of stent-graft technology however needs to be adapted to the specific
88 features of the ascending aorta.

89

90 Abstract word count: 248

91 Central Message

92 TEVAR in type A aortic dissection is feasible in selected patients. Favorable
93 aortic remodelling occurs in type A (and B) dissections. Thus TEVAR may be an
94 option in patients at high risk for surgery.

95

96 Perspective Statement

97 TEVAR offers a potential treatment option in a subset of patients with type A
98 aortic dissection at high surgical risk but with suitable anatomy. With TEVAR, 30
99 day survival is >90% in these high surgical risk patients. With this proof of
100 concept study, broader application may be possible with further specific
101 technological advances.

102

103 Central Picture legend

104 Successful interventional treatment of a type A aortic dissection using TEVAR

105

106 INTRODUCTION

107

108 The surgical mortality and morbidity remains high for proximal (Stanford
109 type A) aortic dissections, particularly in the elderly with significant co-
110 morbidities, despite recent strides to improve its surgical technique and
111 management (1, 2). Considering the Western demographics with increasing
112 aging population and variety of co-morbidities which portend inherent increased
113 surgical risks, the concept of endovascular stent-grafting also known as thoracic
114 endovascular aortic repair (TEVAR) (a catheter-based non-surgical technique) in
115 patients with thoracic aortic disease is increasingly attractive, propelled by the
116 desire to minimize surgical risks. TEVAR has been shown to initiate healing and
117 remodelling of the dissected aorta, by excluding and depressurizing the false
118 lumen (3-5). To date, TEVAR strategies appear encouraging in the treatment of
119 various aortic pathologies (6-10). The technology has been embraced without
120 level I evidence for the treatment of distal (Stanford type B) aortic dissections,
121 and even used to treat acute proximal (Stanford type A) aortic dissections (11).
122 However, the complexity of the anatomy in the ascending aorta continues to be a
123 major obstacle for the use of endovascular technologies.

124 Acute type A aortic dissection usually requires very urgent surgical repair
125 of the ascending aorta (12-14); selected cases however may qualify for TEVAR as
126 an option in scenarios of unacceptably high surgical risk. According to the
127 International Registry of Acute Aortic Dissections (IRAD), 86% patients qualify
128 for surgical replacement of the ascending aorta, 23% or 12% require additional
129 partial or total arch replacement, respectively (15). Overall, on aggregate 91% of
130 patients in this registry underwent surgical repair under cardiopulmonary
131 bypass with 25% in-hospital mortality (15, 16). A less traumatic repair of type A
132 aortic dissection using TEVAR, where applicable, may potentially lower the
133 procedural/in-hospital mortality risk, particularly as the technology improves.

134 Surgical repair leaves a patent false lumen in both the aortic arch and
135 descending aorta in 75% patients, those who survive often require distal re-
136 interventions (15, 16). One solution may be a two-stage hybrid procedure,
137 whereby initially, surgery is performed to replace the ascending aorta together
138 with aorto-brachiocephalic artery bypass without hypothermic circulatory

139 arrest. This is followed on a second occasion by surgery for left carotid artery
140 bypass and TEVAR to retrogradely place an endovascular stent-graft in the
141 thoracic aorta transfemorally in the same setting. The stent-graft excludes the
142 retrogradely perfused distal false lumen (17). The objective of such an approach
143 is to avoid surgery on the arch, and to complete the repair with an aortic stent-
144 graft in a minimally invasive way. Such approach not only minimizes the
145 procedural risks, but also enables careful evaluation of the distal false lumen
146 prior to stent-graft placement. Alternatively, one-stage hybrid procedures
147 combining open (surgical) insertion of a tube-graft in the ascending aorta with
148 head vessel transposition and antegradely placing an endovascular stent-graft
149 in the arch and descending aorta are feasible (18), but require the skills of both a
150 cardiac and endovascular specialist and lack the precision of the two-stage
151 hybrid procedure (19). Moreover, there is some resistance to apply such one-
152 stage hybrid procedures in acute type A aortic dissections, because experts are
153 aware that the fragile outer aortic wall and friable dissecting lamella are prone to
154 injury or perforation by antegrade positioning of the stent-graft under
155 conditions of circulatory arrest. At present there are no dedicated stent-grafts for
156 the ascending aorta, in particular for the repair of aortic dissections; such
157 challenges will certainly be addressed by customized stent-graft technology in
158 the near future. Nevertheless, the concept of a one-stage hybrid repair with
159 antegrade stent-graft placement may become part of a therapeutic
160 armamentarium for complex type A dissections with distal malperfusion; while a
161 multi-stage hybrid repair incorporating retrograde stent-graft placement may
162 become a preferred option in stable situations.

163 From an anatomical perspective, 30–50% patients with type A aortic
164 dissection are amenable to TEVAR (20, 21). Thus in the future more patients may
165 be considered suitable for TEVAR with life-long follow-up. The ultimate goal is a
166 fully catheter-based approach to repair the ascending aorta that minimizes
167 procedural risk and initiates healing (as documented in type B dissections where
168 interventional entry closure is associated with thrombosis of the false lumen and
169 favorable aortic remodelling) (3, 4, 6, 7). Such approach is feasible with current
170 technology (22-25). Here, we describe our 12-case series of type A aortic dissections
171 treated using TEVAR.

172

173 **METHODS**

174

175 *Patient selection*

176 Between year 2009 and 2016, 12 patients with type A aortic dissection
177 consisting of an isolated dissection entry in the ascending aorta, referred to the
178 University Heart Centre (Rostock, Germany), CHU (Liege, Belgium) and Royal
179 Brompton Hospital (London, UK) were selected and subjected to TEVAR. These
180 patients were selected for TEVAR because of high co-morbidities and anatomic
181 suitability, e.g. aortic dimensions suitable to accommodate a ready-made
182 commercial stent-graft. All had elevated anesthetic risk score (American Society
183 of Anesthesiologists classification IV or greater), New York Heart Association
184 class III or IV, chronic lung disease and/or renal impairment. Decisions regarding
185 treatment required consensus between cardiac surgeons and cardiologists, with
186 the patients giving informed written consent. TEVAR in this setting was
187 approved by the internal review board of each center. All patients had EKG-gated
188 computed tomography (CT) (Figure 1) and echocardiography for the diagnosis
189 and assessment of aortic dissection. Echocardiography allowed assessment of
190 the aortic valve, left ventricular function, presence/absence of tamponade, and
191 interrogation of the supra-aortic vessels.

192

193 *TEVAR procedure*

194 Procedural planning was based on contrast-enhanced EKG-gated CT
195 (Figure 1), which was evaluated using standard software (TeraRecon, or
196 3Mensio) to select the appropriate stent-graft size; the diameter of the stent-
197 graft was chosen according to an estimate of the previous (before dissection)
198 aortic dimension to avoid oversizing. The stent-grafts used were usually ZENITH
199 TX2 (Cook, Bloomington, Indiana), GORE C-Tag (Gore Ltd. London, UK) or Relay
200 NBS (Bolton, Barcelona, Spain). They are made of a self-expanding nitinol stent
201 platform covered with polyester fabric. They are packed and mounted onto a
202 catheter-based delivery system. Figure 2 and Videos 1-3 show a typical TEVAR
203 procedure. With the patient under general anesthesia, a temporary pacing wire
204 was placed in the right ventricle and vascular access for the TEVAR device (22-

205 24F) obtained via right femoral arterial cut-down. The true lumen of the aorto-
206 ilio-femoral arterial route was navigated using a soft long hydrophilic guide wire
207 (Terumo, Inc.) protruding ahead of a pigtail catheter to reach the left ventricle
208 under fluoroscopy and ultrasound guidance (transesophageal
209 echocardiography) (26). Once the pigtail is in the left ventricle, the soft
210 hydrophilic guide wire was exchanged to a stiff 270cm length guide wire through
211 the pigtail catheter. The stiff guide wire has a soft spiral tip that sits within the
212 left ventricular cavity. The stent-graft was then delivered along the stiff guide
213 wire to its intended position, where its distal landing zone is between 'distal to
214 the coronary ostia' and 'proximal to the brachiocephalic artery' in the ascending
215 aorta. In this position, the distal tip of the delivery system may cross the aortic
216 valve. For stent-graft deployment, rapid right ventricular pacing at 180 bpm was
217 used to reduce the systolic blood pressure to ≤ 50 mmHg in order to avoid
218 displacement (windsock effect) of the stent-graft during its deployment, thus
219 enabling its precise placement. At the end of the procedure, the temporary
220 pacing wire was removed, the femoral artery access site closed, and the patient
221 extubated and transferred to the coronary care unit. Procedural success was
222 defined as successful placement of the stent-graft in its intended position with
223 sealing of the entry tear.

224

225 *Follow-up*

226 Overall aortic and true lumen diameters were assessed at the level of
227 sinotubular junction, ostium of the brachiocephalic artery and left subclavian
228 artery. Follow-up CT scans were performed approximately at 6 months and then
229 annually post TEVAR.

230

231 *Statistical analysis*

232 Descriptive statistic was used to characterize patients, procedural data
233 and individual survival.

234

235 **RESULTS**

236

237 A total of 12 patients with proximal (type A) aortic dissection were

238 selected for TEVAR (Table 1). There were 10 DeBakey type II and 2 DeBakey
239 type I dissections. The mean age \pm standard deviation (SD) was 81 ± 7 years;
240 male:female ratio was 9:3. All patients were of advanced age with chronic lung
241 disease, coronary artery disease and/or renal impairment. The mean EuroSCORE
242 II was 9.1 ± 4.5 (SD). The median time from onset of symptoms/diagnosis to
243 TEVAR was 24 days. There were 6 cases of acute (≤ 14 days after symptom onset)
244 and 6 cases of subacute (15 days to 3 months) or chronic (> 3 months) aortic
245 dissections. The false lumen of the dissection expanded significantly causing
246 various complications, including dyspnoea, hoarseness or laryngeal nerve
247 dysfunction. There was a history of chest and back pain in all cases. There were
248 no significant aortic insufficiency, no clinically apparent distal malperfusion
249 syndromes and no distal interventions required.

250 Procedural success was 91.7% (11/12) (Table 1). There was one death
251 due to cardiac tamponade from wire induced perforation of the left ventricle. All
252 remaining 11 patients were discharged alive within 2 weeks of TEVAR. The
253 mean procedural time was 86 ± 33 (SD) minutes. Stent-grafts were deployed
254 under rapid right ventricular pacing which achieved a mean systolic pressure of
255 34 ± 15 (SD) mmHg. The mean follow-up time was 21.1 ± 11.8 (SD) months
256 (range 0 - 36 months) post TEVAR. There were 4 deaths, one each at 15, 19, 23
257 and 36 months (Table 1). All appeared to have died from natural causes. The
258 mean survival in those who died during follow-up was 23 months.

259 Follow-up CT scans revealed thrombosis or remodelling of the stent-graft
260 excluded false lumen. The diameter of the aorta at the sinotubular junction was
261 not enlarged and remained similar to the normal aorta post TEVAR (Figure 3).

262

263 **DISCUSSION**

264

265 There is general consensus that proximal aortic dissection or any major
266 pathology involving the ascending aorta should be subjected to surgical repair.
267 However, 10-30% of patients with acute type A aortic dissection are considered
268 too high risk for surgical repair and would therefore receive only medical
269 therapy with associated high mortality of $\approx 60\%$ in the intermediate term (13, 15,
270 27, 28). Surgical mortality is 10-25% (16, 27) depending on the complexity of the

271 operation and the clinical status of the patient. In our hands, the procedural
272 mortality of TEVAR was 8%, which compares favorably with the published early
273 endovascular mortality of 11% [18, 19]. Interestingly, the most anticipated
274 complications such as major stroke did not occur. One minor stroke (transient)
275 and one death from guidewire perforation of the left ventricle leading to fatal
276 tamponade occurred.

277 We estimate the number of TEVAR procedures performed in this study
278 relative to all emergency surgeries for type A aortic dissection in our 3 centers to
279 be $\approx 2\%$, or 6-17% of inoperable type A cases (assuming the incidence of type A
280 dissection ≈ 40 cases/year for a typical aortic center; therefore across 3 centers
281 spanning the study period of 6 years, the total number of cases = 40 cases x 6
282 years x 3 centers = 720 cases; generally 10-30% of type A dissections are
283 inoperable (15)).

284 Successful sealing of the false lumen entry with no development of
285 proximal type I endoleak were achieved. During follow-up, no cases of endoleak
286 were identified which is encouraging and different to $\approx 10\%$ incidence reported
287 elsewhere (29). In selecting the appropriate size of stent-grafts, we chose the
288 diameter of the stent-grafts according to an estimate of the previous (before
289 dissection) aortic dimension to avoid oversizing. The goal was to re-shape the
290 dissected ascending aorta, cover the entry tear and depressurize the false lumen
291 (30, 31); there is a fine balance between fixation to the aortic wall and the degree
292 of intimal injury caused by the self-expanding stent-graft. However, once
293 precisely deployed, the process of remodelling of the false lumen appears similar
294 between the proximal and distal dissection, and takes place usually within one
295 year, similar to that reported elsewhere (32, 33). Most of our cases were
296 DeBakey type II dissections, and even in the 2 cases of type I dissection (patients
297 2 and 3 in Table 1), favorable aortic remodelling of the descending aorta were
298 observed. It seems that the therapeutic concept of closing the entry and
299 depressurizing the false lumen in type B (distal) aortic dissection holds true also
300 in type A (ascending) aortic dissection (3, 4). As long as the false lumen is
301 thrombosed and depressurized, survival even with type A aortic dissection can
302 be improved by TEVAR (34). In addition, the patients' exposure to unacceptable
303 risk of surgery is minimized.

304 Current literature (mostly single or small case series) underlines the
305 feasibility of proximal endovascular procedures over more than 10 years,
306 performed by surgeons and interventionalists (Table 2). Our series over 6 years
307 with a mean follow-up of >20 months (range up to 3 years) underlines the fact
308 that in the setting of significant co-morbidities representing high surgical risk
309 but with suitable anatomy, TEVAR can be a viable alternative to surgical repair.
310 In other words, it is feasible to avoid high risk/ complex surgery, and apply a less
311 traumatic intervention to obtain a similar or better short-term outcome in a
312 subset of elderly patients with significant co-morbidities. The advantages of
313 TEVAR includes the avoidance of thoracotomy, cardiopulmonary bypass,
314 selective head perfusion and associated surgical risks in an elderly population,
315 often in a critical condition (35). If the high initial $\approx 60\%$ mortality of type A
316 aortic dissection can be successfully lowered by TEVAR, such less traumatic
317 strategy may potentially become an option in a broader spectrum of patients
318 (27). As TEVAR is a fairly expensive procedure, its associated lower
319 risks/complications and shorter lengths of hospital stay compared to surgery
320 may potentially demonstrate its advantages in terms of cost and clinical outcome
321 over surgery.

322 TEVAR will not be feasible in every patient; the most suitable anatomy is
323 where the entry tear of the dissection is located in the middle portion of the
324 ascending aorta. Entry tears close to the coronaries or aortic valve lack a suitable
325 length of landing zone. Entry tears close to the brachiocephalic artery would
326 require complex branching/fenestration strategies. Currently, only a limited
327 number of choices are available regarding the type of stent-graft and delivery
328 system because relatively large diameter and short length stent-grafts are
329 required. Existing delivery systems need to be modified for ascending aorta
330 intervention: a long nosecone can either damage the aortic valve or increase the
331 chance of left ventricular perforation by the stiff guidewire, as occurred in one of
332 our patients.

333 On a technical note, with the use of rapid ventricular pacing no
334 misplacement of these short stent-grafts was seen. Pacing is probably the most
335 efficient method to avoid windsock effect of the left ventricle, enabling precise
336 stent-graft placement. Transoesophageal echocardiography is also useful in

337 guiding stent- graft positioning and assessing sealing of the entry tear (26).

338 It should be emphasized that a multidisciplinary team, consisting of
339 cardiac and vascular surgeons and cardiologists, should select suitable patients
340 for the procedure, similar to transcatheter aortic valve replacement (TAVR).
341 Looking forward, we believe TEVAR in the ascending aorta is a definitive
342 solution for patients not accepted for surgery, or a bridging solution in case of
343 unclear neurological diagnosis (e.g., major stroke) to buy time for reconstructive
344 surgery. Selection process in patients not suitable for surgical valve replacement
345 may even be conceivable for combined TAVR- TEVAR technology, in an attempt
346 to treat variants of aortic dissection including those with compromised aortic
347 valve function. It should also be emphasised that in the acute setting there is a
348 need to identify and transfer type A aortic dissection patients to a specialized
349 unit as quickly as possible; once the dissection has produced coronary
350 obstruction (usually the right coronary artery) with ensuing (right) ventricular
351 infarction and heart failure, it is a difficult situation to retrieve by either
352 endografting or conventional surgery.

353

354 *Study limitations*

355 While we could demonstrate proof of concept and feasibility of TEVAR in
356 the ascending aorta with encouraging results, we did not examine possible
357 detrimental effects such as stiffening of the ascending aorta by the stent, lowered
358 vascular compliance, negative effects on the aortic valve function or
359 hypertension in this observational study. Our sample size is relatively small, but it
360 represents one of the biggest case-series in the field and supports the feasibility of
361 TEVAR in practical terms. We have no control group (medically treated or surgery)
362 for comparison, but historical data suggests that surgery confers 25% peri-operative
363 mortality, and medical treatment is associated with 60% mortality (13, 15, 27, 28). A
364 propensity-matched comparison prior to any randomized study would probably
365 be the next step to strengthen the data on TEVAR in the proximal aorta; current
366 technology is unlikely to allow a broader application yet.

367

368 *Conclusion*

369 TEVAR is feasible and reveals promising early results in selected patients

370 with proximal (type A) aortic dissection who are poor candidates for surgical repair.
371 The current iteration of stent-graft technology however needs to be adapted to the
372 specific features of the ascending aorta before TEVAR as a concept emerges for
373 broader applications in the proximal aorta.
374

ACCEPTED MANUSCRIPT

375 Figure legends

376

377 Figure 1. From top to bottom: 2-dimensional transverse and coronal section of a
378 localized proximal aortic dissection (type A) with a large entry between the
379 aortic valve and brachiocephalic artery; 3-dimensional reconstruction prior to
380 treatment.

381

382 Figure 2. TEVAR procedural sequence for placing a covered stent-graft to treat a
383 type A aortic dissection. (A) Aortogram and set-up showing a right ventricular
384 pacing wire and transesophageal echo probe; (B) Stent-graft deployment during
385 rapid pacing; (C) Completed deployment of the stent-graft; (D) Aortogram
386 demonstrating procedural success.

387

388 Figure 3. From top to bottom: 2-dimensional transverse and coronal sections of a
389 proximal (type A) aortic dissection before (left) and after stent-grafting (right),
390 demonstrating TEVAR reconstruction and remodelling of the aorta. The bottom
391 panels demonstrate the successful intervention in 3-dimensional reconstruction.

392

393 Video 1. Before TEVAR. Digital subtraction angiogram showing a large tear in the
394 ascending aorta, and a marker pigtail, pacing wire and transoesophageal
395 echocardiography probe in place.

396

397 Video 2. During TEVAR. Fluoroscopic display of the launch of a self-expanding
398 Viabahn stent-graft in the brachiocephalic artery followed by a self-expanding C-
399 Tag stent-graft covering the ascending aorta under rapid pacing.

400

401 Video 3. After TEVAR. Completion angiogram after placement of the Viabahn
402 stent-graft in the brachiocephalic artery and C-Tag stent-graft in the ascending
403 aorta; the entry to the dissection is sealed and flow is preserved to the
404 brachiocephalic and coronary arteries.

405

406

References

407

- 408 1. Suenaga E, Sato M, Fumoto H. Ascending aortic replacement for acute type
409 A aortic dissection in octogenarians. *Gen Thorac Cardiovasc Surg* 2016
410 Mar;64(3):138-43.
- 411 2. Rylski B, Hoffmann I, Beyersdorf F, et al. Acute aortic dissection type A:
412 age-related management and outcomes reported in the German Registry for
413 Acute Aortic Dissection Type A (GERAADA) of over 2000 patients. *Ann Surg* 2014
414 Mar;259(3):598-604.
- 415 3. Nienaber CA, Fattori R, Lund G, et al. Nonsurgical reconstruction of
416 thoracic aortic dissection by stent-graft placement. *N Engl J Med* 1999 May
417 20;340(20):1539-45.
- 418 4. Dake MD, Kato N, Mitchell RS, et al. Endovascular stent-graft placement
419 for the treatment of acute aortic dissection. *N Engl J Med* 1999 May
420 20;340(20):1546-52.
- 421 5. Resch TA, Delle M, Falkenberg M, et al. Remodeling of the thoracic aorta
422 after stent grafting of type B dissection: a Swedish multicenter study. *J*
423 *Cardiovasc Surg (Torino)* 2006 Oct;47(5):503-8.
- 424 6. Eggebrecht H, Nienaber CA, Neuhauser M, et al. Endovascular stent-graft
425 placement in aortic dissection: a meta-analysis. *Eur Heart J* 2006 Feb;27(4):489-
426 98.
- 427 7. Fattori R, Nienaber CA, Rousseau H, et al. Results of endovascular repair
428 of the thoracic aorta with the Talent Thoracic stent graft: the Talent Thoracic
429 Retrospective Registry. *J Thorac Cardiovasc Surg* 2006 Aug;132(2):332-9.
- 430 8. Hassoun HT, Matsumura JS. The COOK TX2 thoracic stent graft:
431 preliminary experience and trial design. *Semin Vasc Surg* 2006 Mar;19(1):32-9.
- 432 9. Kwolek CJ, Fairman R. Update on thoracic aortic endovascular grafting
433 using the medtronic talent device. *Semin Vasc Surg* 2006 Mar;19(1):25-31.
- 434 10. Makaroun MS, Dillavou ED, Kee ST, et al. Endovascular treatment of
435 thoracic aortic aneurysms: results of the phase II multicenter trial of the GORE
436 TAG thoracic endoprosthesis. *J Vasc Surg* 2005 Jan;41(1):1-9.

- 437 11. Szeto WY, McGarvey M, Pochettino A, et al. Results of a new surgical
438 paradigm: endovascular repair for acute complicated type B aortic dissection.
439 *Ann Thorac Surg* 2008 Jul;86(1):87-93; discussion -4.
- 440 12. Santini F, Montalbano G, Casali G, et al. Clinical presentation is the main
441 predictor of in-hospital death for patients with acute type A aortic dissection
442 admitted for surgical treatment: a 25 years experience. *Int J Cardiol* 2007 Feb
443 14;115(3):305-11.
- 444 13. Centofanti P, Flocco R, Ceresa F, et al. Is surgery always mandatory for
445 type A aortic dissection? *Ann Thorac Surg* 2006 Nov;82(5):1658-63; discussion
446 64.
- 447 14. Akin I, Nienaber C. [Established Indications for Invasive Treatment of
448 Thoracic Aortic Aneurysm]. *Dtsch Med Wochenschr* 2015 Nov;140(23):1747-52.
- 449 15. Pape LA, Awais M, Woznicki EM, et al. Presentation, Diagnosis, and
450 Outcomes of Acute Aortic Dissection: 17-Year Trends From the International
451 Registry of Acute Aortic Dissection. *J Am Coll Cardiol* 2015 Jul 28;66(4):350-8.
- 452 16. Trimarchi S, Nienaber CA, Rampoldi V, et al. Contemporary results of
453 surgery in acute type A aortic dissection: The International Registry of Acute
454 Aortic Dissection experience. *J Thorac Cardiovasc Surg* 2005 Jan;129(1):112-22.
- 455 17. Shah A, Coulon P, de Chaumaray T, et al. Novel technique: staged hybrid
456 surgical and endovascular treatment of acute Type A aortic dissections with
457 aortic arch involvement. *J Cardiovasc Surg (Torino)* 2006 Oct;47(5):497-502.
- 458 18. Diethrich EB, Ghazoul M, Wheatley GH, et al. Surgical correction of
459 ascending type a thoracic aortic dissection: simultaneous endoluminal exclusion
460 of the arch and distal aorta. *J Endovasc Ther* 2005 Dec;12(6):660-6.
- 461 19. Dobrilovic N, Elefteriades JA. Stenting the descending aorta during repair
462 of type A dissection: technology looking for an application? *J Thorac Cardiovasc*
463 *Surg* 2006 Apr;131(4):777-8.
- 464 20. Moon MC, Greenberg RK, Morales JP, et al. Computed tomography-based
465 anatomic characterization of proximal aortic dissection with consideration for
466 endovascular candidacy. *J Vasc Surg* 2011 Apr;53(4):942-9.
- 467 21. Sobocinski J, O'Brien N, Maurel B, et al. Endovascular approaches to acute
468 aortic type A dissection: a CT-based feasibility study. *Eur J Vasc Endovasc Surg*
469 2011 Oct;42(4):442-7.

- 470 22. Ihnken K, Sze D, Dake MD, Fleischmann D, Van der Starre P, Robbins R.
471 Successful treatment of a Stanford type A dissection by percutaneous placement
472 of a covered stent graft in the ascending aorta. *J Thorac Cardiovasc Surg* 2004
473 Jun;127(6):1808-10.
- 474 23. Wang ZG, Massimo CG, Li M, et al. Deployment of endograft in the
475 ascending aorta to reverse type A aortic dissection. *Asian J Surg* 2003
476 Apr;26(2):117-9.
- 477 24. Zhang H, Li M, Jin W, Wang Z. Endoluminal and surgical treatment for the
478 management of Stanford Type A aortic dissection. *Eur J Cardiothorac Surg* 2004
479 Oct;26(4):857-9.
- 480 25. Zimpfer D, Czerny M, Kettenbach J, et al. Treatment of acute type a
481 dissection by percutaneous endovascular stent-graft placement. *Ann Thorac*
482 *Surg* 2006 Aug;82(2):747-9.
- 483 26. Koschyk DH, Nienaber CA, Knap M, et al. How to guide stent-graft
484 implantation in type B aortic dissection? Comparison of angiography,
485 transesophageal echocardiography, and intravascular ultrasound. *Circulation*
486 2005 Aug 30;112(9 Suppl):I260-4.
- 487 27. Rampoldi V, Trimarchi S, Eagle KA, et al. Simple risk models to predict
488 surgical mortality in acute type A aortic dissection: the International Registry of
489 Acute Aortic Dissection score. *Ann Thorac Surg* 2007 Jan;83(1):55-61.
- 490 28. Tsai TT, Evangelista A, Nienaber CA, et al. Long-term survival in patients
491 presenting with type A acute aortic dissection: insights from the International
492 Registry of Acute Aortic Dissection (IRAD). *Circulation* 2006 Jul 4;114(1
493 Suppl):I350-6.
- 494 29. Ueda T, Fleischmann D, Dake MD, Rubin GD, Sze DY. Incomplete endograft
495 apposition to the aortic arch: bird-beak configuration increases risk of endoleak
496 formation after thoracic endovascular aortic repair. *Radiology* 2010
497 May;255(2):645-52.
- 498 30. Ye C, Chang G, Li S, et al. Endovascular stent-graft treatment for Stanford
499 type A aortic dissection. *Eur J Vasc Endovasc Surg* 2011 Dec;42(6):787-94.
- 500 31. Metcalfe MJ, Karthikesalingam A, Black SA, Loftus IM, Morgan R,
501 Thompson MM. The first endovascular repair of an acute type A dissection using
502 an endograft designed for the ascending aorta. *J Vasc Surg* 2012 Jan;55(1):220-2.

- 503 32. Lu Q, Feng J, Zhou J, et al. Endovascular repair of ascending aortic
504 dissection: a novel treatment option for patients judged unfit for direct surgical
505 repair. *J Am Coll Cardiol* 2013 May 7;61(18):1917-24.
- 506 33. Ronchey S, Serrao E, Alberti V, et al. Endovascular stenting of the
507 ascending aorta for type A aortic dissections in patients at high risk for open
508 surgery. *Eur J Vasc Endovasc Surg* 2013 May;45(5):475-80.
- 509 34. Bossone E, Evangelista A, Isselbacher E, et al. Prognostic role of
510 transesophageal echocardiography in acute type A aortic dissection. *Am Heart J*
511 2007 Jun;153(6):1013-20.
- 512 35. Comas GM, Leshnower BG, Halkos ME, et al. Acute type a dissection:
513 impact of antegrade cerebral perfusion under moderate hypothermia. *Ann*
514 *Thorac Surg* 2013 Dec;96(6):2135-41.
- 515
516

Table 1

Patient	Age & Sex	Diagnosis	Euroscore II	SG	SG size DxL (mm)	Procedure duration (min)	Procedural complications	Follow-up (months)
1	74 M	cTAAD (DeBakey II)	6.9	Cook	34x77	90	None	32
2	75 M	aTAAD (DeBakey I)	8.1	Bolton NBS	34x60	140	None	29
3	87 M	aTAAD (DeBakey I)	13.4	Bolton NBS	34x60	79	None	35
4	89 M	cTAAD (DeBakey II)	15.0	Cook	36x77	149	None	15, †
5	90 M	cTAAD (DeBakey II)	19.3	Cook	36x77	70	Ventricular rupture, tamponade	0, †
6	69 M	aTAAD (DeBakey II)	3.9	Cook	34x77	61	None	36, †
7	75 M	cTAAD (DeBakey II)	4.9	Bolton NBS	34x60	70	None	24
8	87 M	cTAAD (DeBakey II)	9.4	Cook	36x77	49	Minor Stroke	15
9	87 F	aTAAD (DeBakey II, post TAVR)	7	Optimed	32x50	120	None	23, †
10	83 M	cTAAD (DeBakey II)	6.9	Cook	34x77	89	None	19, †
11	75 F	aTAAD (DeBakey II)	5.9	Cook	34x77	60	none	5
12	75 F	aTAAD (DeBakey II)	8.9	Gore + Viabahn in innominate artery	34x100	60	none	0


Abbreviations: aTAAD (acute type A aortic dissection), cTAAD (subacute or chronic type A aortic dissection), D (diameter), F (female), L (length), M (male), NBS (non-bare stent), SG (stent-graft), TAVR (transcatheter aortic valve replacement). † indicates deceased.

Table 2


Author	Year	N	Acute n (%)	Stent-graft	Access route	Follow-up months	Early mortality n (%)	Cause of death	Complications	Re-intervention
Dorros et al	2000	1	1 (100)	Lecteba	RFV Trans-septal	1	1 (100)	Cardiac arrest	-	-
Wang et al	2003	1	1 (100)	Covered Z-stent	Aorta	12	0	-	-	-
Ihnken et al	2004	1	1 (100)	Gore	-	none	0	-	-	-
Zhang et al	2004	1	0	Gianturco Z-stent	TF	21	0	-	Aortic regurgitation	Open surgery
Zimpfer et al	2006	1	1 (100)	Jotec	TF	1	0	-	-	-
Senay et al	2007	1	1 (100)	Medtronic	TF	none	0	-	Endoleak	-
Palma et al	2007	1	0	Braille Biomed	TF	none	1 (100)	Cardiac arrest stent migration	-	-
Ye et al	2011	10	6 (60)	Various	2 LCCA, 8 TF	35.5	1 (10)	Gastrointestinal bleeding	-	Balloon dilatation for endoleak
Metcalfe et al	2012	1	1 (100)	Medtronic	TF	none	0	-	-	-
Gustavo et al	2012	1	1 (100)	Cook	Aorta	32	0	-	Tachycardia	-
Ronchey et al	2013	4	4 (100)	Cook	TF	15 (4-39)	0	-	-	-
Bahaeddin et al	2013	1	0	Cook	TA	1	0	-	Aortic regurgitation	-
Eric et al	2013	1	1 (100)	Cook	TA	none	0	-	-	-
Kölbl et al	2013	1	1 (100)	Cook	TA	6	0	-	-	-
Frederic et al	2013	1	1 (100)	Jotec	TA	none	0	-	-	-
Lu et al	2013	15	5 (33)	Cook	-	22 (12-31)	0	-	Arrhythmia	Angioplasty and stenting of left renal artery
Yuuya et al	2014	1	1 (100)	Gore	RCA	none	0	-	-	-
Kimberly et al	2014	1	1 (100)	Medtronic	TF	none	0	-	-	-
Vallabhajosyula et al	2015	6	3 (50)	Cook Amplatzer	4 TA, 1 TF, 1 LCCA	33 (3-57)	0	-	Endoleak Stroke	Re-stenting for endoleak
Roselli et al	2015	18	9 (50)	Cook, Gore, Medtronic	5 TA, 4 TAX, 9 TF	12 median	3 (17)	Coronary obstruction, aortic rupture, tamponade	Contained aortic rupture, endoleak, stent migration, apical IPA	Stent extension, open surgery

Abbreviations: LCCA (left common carotid artery), N (number), PA (pseudoaneurysm), RCA (right carotid artery), RFV (right femoral vein), TA (transapical), TA_x (transaxillary), TF (transfemoral).




ACCEPTED MANUSCRIPT



MANUSCRIPT



ACCEPTED





ACCEPTED MANUSCRIPT